Skip to main content

Articles

Page 1 of 35

  1. Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes....

    Authors: Jonathan J. Park, Adan Codina, Lupeng Ye, Stanley Lam, Jianjian Guo, Paul Clark, Xiaoyu Zhou, Lei Peng and Sidi Chen
    Citation: Journal of Hematology & Oncology 2022 15:172
  2. Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognos...

    Authors: Nicole Bäumer, Annika Scheller, Lisa Wittmann, Andreas Faust, Mara Apel, Subbaiah Chary Nimmagadda, Christiane Geyer, Katharina Grunert, Neele Kellmann, Matthias Peipp, Sareetha Kailayangiri, Matias Ezequiel Gutierrez Suburu, Cristian A. Strassert, Mathias Schenk, Lilo Greune, Christian Rüter…
    Citation: Journal of Hematology & Oncology 2022 15:171
  3. Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccin...

    Authors: Ludovic Jondreville, Maud D’Aveni, Hélène Labussière-Wallet, Amandine Le Bourgeois, Alban Villate, Ana Berceanu, Silvia-Maria Bezsera, Anne Thiebaut, Marion Boissard-Simonet, Marlène Legrand, Jérôme Cornillon, Marie-Thérèse Rubio, Patrice Chevallier and Stéphanie Nguyen
    Citation: Journal of Hematology & Oncology 2022 15:169
  4. Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor prognosis. Proteogenomic characterization and integrative proteomic analysis provide a functional context to annotate genomic abnormal...

    Authors: Yexin Tong, Mingjun Sun, Lingli Chen, Yunzhi Wang, Yan Li, Lingling Li, Xuan Zhang, Yumeng Cai, Jingbo Qie, Yanrui Pang, Ziyan Xu, Jiangyan Zhao, Xiaolei Zhang, Yang Liu, Sha Tian, Zhaoyu Qin…
    Citation: Journal of Hematology & Oncology 2022 15:168
  5. A novel recombinant SIRPα-Fc fusion protein, IMM01, was constructed and produced using an in-house developed CHO-K1 cell expression system, and the anti-tumor mechanism of IMM01 targeting the CD47-SIRPα pathwa...

    Authors: Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang…
    Citation: Journal of Hematology & Oncology 2022 15:167
  6. Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). The first-in-class covalent BTK inhibitor,...

    Authors: Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd and Jennifer A. Woyach
    Citation: Journal of Hematology & Oncology 2022 15:166
  7. The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 i...

    Authors: Kim Kramer, Neeta Pandit-Taskar, Brian H. Kushner, Pat Zanzonico, John L. Humm, Ursula Tomlinson, Maria Donzelli, Suzanne L. Wolden, Sophia Haque, Ira Dunkel, Mark M. Souweidane, Jeffrey P. Greenfield, Satish Tickoo, Jason S. Lewis, Serge K. Lyashchenko, Jorge A. Carrasquillo…
    Citation: Journal of Hematology & Oncology 2022 15:165
  8. Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly valuable treatment opti...

    Authors: Nina Lamers-Kok, Denise Panella, Anna-Maria Georgoudaki, Haiping Liu, Didem Özkazanc, Lucia Kučerová, Adil Doganay Duru, Jan Spanholtz and Monica Raimo
    Citation: Journal of Hematology & Oncology 2022 15:164
  9. Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatri...

    Authors: Simona Caruso, Biagio De Angelis, Francesca Del Bufalo, Roselia Ciccone, Samantha Donsante, Gabriele Volpe, Simona Manni, Marika Guercio, Michele Pezzella, Laura Iaffaldano, Domenico Alessandro Silvestris, Matilde Sinibaldi, Stefano Di Cecca, Angela Pitisci, Enrico Velardi, Pietro Merli…
    Citation: Journal of Hematology & Oncology 2022 15:163
  10. No fully validated risk-stratification strategies have been established in China where colonoscopies resources are limited. We aimed to develop and validate a fecal immunochemical test (FIT)-based risk-stratif...

    Authors: Shengbing Zhao, Shuling Wang, Peng Pan, Tian Xia, Rundong Wang, Quancai Cai, Xin Chang, Fan Yang, Lun Gu, Zixuan He, Jiayi Wu, Qianqian Meng, Tongchang Wang, Qiwen Fang, Xiaomei Mou, Honggang Yu…
    Citation: Journal of Hematology & Oncology 2022 15:162
  11. Hepatocarcinogenesis is driven by necroinflammation or metabolic disorders, and the underlying mechanisms remain largely elusive. We previously found that retinoic acid-inducible gene-I (RIG-I), a sensor for r...

    Authors: Zhenyang Li, Ye Zhou, Kaiwei Jia, Yingyun Yang, Liyuan Zhang, Suyuan Wang, Yue Dong, Mu Wang, Yunhui Li, Shan Lu, Wannian Zhang, Luxin Zhang, Yiwen Fan, Dingji Zhang, Nan Li, Yizhi Yu…
    Citation: Journal of Hematology & Oncology 2022 15:161
  12. Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide. Countless CRC patients undergo disease progression. As a hallmark of cancer, Warburg effe...

    Authors: Xinyang Zhong, Xuefeng He, Yaxian Wang, Zijuan Hu, Huixia Huang, Senlin Zhao, Ping Wei and Dawei Li
    Citation: Journal of Hematology & Oncology 2022 15:160
  13. Authors: Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men…
    Citation: Journal of Hematology & Oncology 2022 15:159

    The original article was published in Journal of Hematology & Oncology 2022 15:113

  14. Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with limited therapeutic options in the advanced setting. Immune checkpoint inhibitors have been shown to have significant clinical activity in i...

    Authors: Mariella Spalato-Ceruso, Fanny Bouteiller, Jean-Philippe Guegan, Maud Toulmonde, Alban Bessede, Michèle Kind, Sophie Cousin, Xavier Buy, Jean Palussiere, François Le Loarer, Berengere Dadone-Montaudie, Marina Pulido and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2022 15:157
  15. Acute myeloid leukemia (AML) is an aggressive blood cancer with poor clinical outcomes. Emerging data suggest that mitochondrial oxidative phosphorylation (mtOXPHOS) plays a significant role in AML tumorigenes...

    Authors: Wonhyoung Seo, Seungyeul Yoo, Yi Zhong, Sang-Hee Lee, Soo-Yeon Woo, Hee-Seon Choi, Minho Won, Taylor Roh, Sang Min Jeon, Kyeong Tae Kim, Prashanta Silwal, Min Joung Lee, Jun Young Heo, Nathan Lawlor, Sup Kim, Dongjun Lee…
    Citation: Journal of Hematology & Oncology 2022 15:156
  16. CPX-351 (Europe: Vyxeos® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In a phase 3 study in older adults with newly di...

    Authors: Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet and Thomas Prebet
    Citation: Journal of Hematology & Oncology 2022 15:155
  17. Identifying T cell epitopes on pancreatic ductal adenocarcinoma (PDAC) associated antigens or neoantigens has been a challenge. In this study, we attempted to identify PDAC T cell epitopes by mass spectrometry...

    Authors: Kenji Fujiwara, Yingkuan Shao, Nan Niu, Tengyi Zhang, Brian Herbst, Mackenzie Henderson, Stephen Muth, Pingbo Zhang and Lei Zheng
    Citation: Journal of Hematology & Oncology 2022 15:154
  18. Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory ro...

    Authors: Binghao Zhao, Huanzhang Li, Yu Xia, Yaning Wang, Yuekun Wang, Yixin Shi, Hao Xing, Tian Qu, Yu Wang and Wenbin Ma
    Citation: Journal of Hematology & Oncology 2022 15:153
  19. After decades of efforts, we have recently made progress into targeting KRAS mutations in several malignancies. Known as the ‘holy grail’ of targeted cancer therapies, KRAS is the most frequently mutated oncog...

    Authors: Kaushal Parikh, Giuseppe Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah and Alfredo Addeo
    Citation: Journal of Hematology & Oncology 2022 15:152
  20. Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducte...

    Authors: Ja Min Byun, Chang-Ki Min, Kihyun Kim, Soo-Mee Bang, Je-Jung Lee, Jin Seok Kim, Sung-Soo Yoon and Youngil Koh
    Citation: Journal of Hematology & Oncology 2022 15:150
  21. JX-594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemotherapy has shown preclinical synergy with oncolytic viruses. We report here the results of t...

    Authors: Maud Toulmonde, Sophie Cousin, Michèle Kind, Jean-Philippe Guegan, Alban Bessede, Francois Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2022 15:149
  22. Acute promyelocytic leukemia (APL) has become curable over 95% patients under a complete chemo-free treatment with all-trans retinoic acid (ATRA) and arsenic trioxide in low-risk patients. Minimizing chemother...

    Authors: Ya-Fang Ma, Ying Lu, Qian Wu, Yin-Jun Lou, Min Yang, Jie-Yu Xu, Cai-Hong Sun, Li-Ping Mao, Gai-Xiang Xu, Li Li, Jian Huang, Huai-Yu Wang, Li-Jiang Lou, Hai-Tao Meng, Jie-Jing Qian, Wen-Juan Yu…
    Citation: Journal of Hematology & Oncology 2022 15:148
  23. Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and maintaining genome stabi...

    Authors: Shuangying Li, Liangliang Wang, Yuanyuan Wang, Changyi Zhang, Zhenya Hong and Zhiqiang Han
    Citation: Journal of Hematology & Oncology 2022 15:147
  24. DNA lesions induced by alkylating agents are repaired by two canonical mechanisms, base excision repair dependent on poly(ADP) ribose polymerase 1 (PARP1) and the other mediated by O6-methylguanine (O6meG)-DNA m...

    Authors: Jodie D. Cropper, Dauren S. Alimbetov, Kevin T. G. Brown, Rostislav I. Likhotvorik, Andrew J. Robles, James T. Guerra, Boxue He, Yidong Chen, Youngho Kwon and Raushan T. Kurmasheva
    Citation: Journal of Hematology & Oncology 2022 15:146
  25. Metastatic prostate cancer (PC) is a leading cause of cancer death in men worldwide. Targeting of the culprits of disease progression is an unmet need. Interleukin (IL)-30 promotes PC onset and development, bu...

    Authors: Carlo Sorrentino, Luigi D’Antonio, Stefania Livia Ciummo, Cristiano Fieni, Lorena Landuzzi, Francesca Ruzzi, Simone Vespa, Paola Lanuti, Lavinia Vittoria Lotti, Pier Luigi Lollini and Emma Di Carlo
    Citation: Journal of Hematology & Oncology 2022 15:145
  26. We assessed the mechanism by which multiple myeloma (MM) shapes the bone marrow (BM) microenvironment and affects MΦ polarization.

    Authors: Katia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, Evgenia Rosenberg, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Lola Weiss, Michal Abraham, Amnon Peled and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2022 15:144
  27. The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, and gene t...

    Authors: Qing Wu, Wei Qian, Xiaoli Sun and Shaojie Jiang
    Citation: Journal of Hematology & Oncology 2022 15:143
  28. Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-...

    Authors: Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu and Kongming Wu
    Citation: Journal of Hematology & Oncology 2022 15:142
  29. Besides featured glucose consumption, recent studies reveal that cancer cells might prefer “addicting” specific energy substrates from the tumor microenvironment (TME); however, the underlying mechanisms remai...

    Authors: Tongyan Liu, Chencheng Han, Panqi Fang, Zhifei Ma, Xiaoxiao Wang, Hao Chen, Siwei Wang, Fanchen Meng, Cheng Wang, Erbao Zhang, Guozhang Dong, Hongyu Zhu, Wenda Yin, Jie Wang, Xianglin Zuo, Mantang Qiu…
    Citation: Journal of Hematology & Oncology 2022 15:141
  30. Pediatric cancers are the driving cause of death for children and adolescents. Due to safety requirements and considerations, treatment strategies and drugs for pediatric cancers have been so far scarcely stud...

    Authors: Hua Wang, Xiaowen Zhou, Chenbei Li, Shuxiang Yan, Chengyao Feng, Jieyu He, Zhihong Li and Chao Tu
    Citation: Journal of Hematology & Oncology 2022 15:140
  31. The booming of gene and cell therapy (GCT) worldwide in recent years has been observed, especially in the field of cancers. In order to provide the comprehensive GCT landscape in China with a focus on differen...

    Authors: Chen Yin, Jianchao Gao, Guanqiao Li, Hongxi Hu, Liyun Zhou, Shuang Lu and Xiaoyuan Chen
    Citation: Journal of Hematology & Oncology 2022 15:139
  32. Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target fo...

    Authors: Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2022 15:138
  33. Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual diseases following systemic therapies in mid-to-late-stage non-small-cell lung cancers (NSCLCs) by multiple studies. How...

    Authors: Siwei Wang, Ming Li, Jingyuan Zhang, Peng Xing, Min Wu, Fancheng Meng, Feng Jiang, Jie Wang, Hua Bao, Jianfeng Huang, Binhui Ren, Mingfeng Yu, Ninglei Qiu, Houhuai Li, Fangliang Yuan, Zhi Zhang…
    Citation: Journal of Hematology & Oncology 2022 15:137
  34. Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evi...

    Authors: Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu…
    Citation: Journal of Hematology & Oncology 2022 15:136
  35. Transforming growth factor-β (TGF-β) signaling has a paradoxical role in cancer progression, and it acts as a tumor suppressor in the early stages but a tumor promoter in the late stages of cancer. Once cancer...

    Authors: Xueke Shi, Jin Yang, Shuzhi Deng, Hongdan Xu, Deyang Wu, Qingxiang Zeng, Shimeng Wang, Tao Hu, Fanglong Wu and Hongmei Zhou
    Citation: Journal of Hematology & Oncology 2022 15:135
  36. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 as an upstream regulator of PD-1 gene ex...

    Authors: Gary Shaw, Ludimila Cavalcante, Francis J. Giles and Alison Taylor
    Citation: Journal of Hematology & Oncology 2022 15:134
  37. Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by genetic signals or drug interventions. Meanwhile, RCD is closely ...

    Authors: Rui Qin, Feng-Ming You, Qian Zhao, Xin Xie, Cheng Peng, Gu Zhan and Bo Han
    Citation: Journal of Hematology & Oncology 2022 15:133

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:151

  38. Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an ...

    Authors: Hailong Tian, Tingting Zhang, Siyuan Qin, Zhao Huang, Li Zhou, Jiayan Shi, Edouard C. Nice, Na Xie, Canhua Huang and Zhisen Shen
    Citation: Journal of Hematology & Oncology 2022 15:132
  39. Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), a...

    Authors: Mina Nikanjam, Shumei Kato and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2022 15:131
  40. circRNA has been established to play a pivotal role in tumorigenesis development in a variety of cancers; nevertheless, the biological functions and molecular mechanisms of hypoxia-induced exosomal circRNAs in...

    Authors: Jiewei Lin, Xinjing Wang, Shuyu Zhai, Minmin Shi, Chenghong Peng, Xiaxing Deng, Da Fu, Jiancheng Wang and Baiyong Shen
    Citation: Journal of Hematology & Oncology 2022 15:128
  41. Myeloid malignancies develop through the accumulation of genetic and epigenetic alterations that dysregulate hematopoietic stem cell (HSC) self-renewal, stimulate HSC proliferation and result in differentiatio...

    Authors: Edward A. Medina, Caroline R. Delma and Feng-Chun Yang
    Citation: Journal of Hematology & Oncology 2022 15:127
  42. The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first co...

    Authors: Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler, Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, Alwin Krämer, Andreas Hochhaus, Sebastian Scholl, Inken Hilgendorf, Tim H. Brümmendorf, Edgar Jost…
    Citation: Journal of Hematology & Oncology 2022 15:126
  43. Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole-genome sequencing (WGS) does not need a prior...

    Authors: Ariane Hallermayr, Tobias Wohlfrom, Verena Steinke-Lange, Anna Benet-Pagès, Florentine Scharf, Ellen Heitzer, Ulrich Mansmann, Christopher Haberl, Maike de Wit, Holger Vogelsang, Markus Rentsch, Elke Holinski-Feder and Julia M. A. Pickl
    Citation: Journal of Hematology & Oncology 2022 15:125
  44. Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute ...

    Authors: Razan Mohty, Rama Al Hamed, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Amer Zeidan and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2022 15:124
  45. The vast majority of our knowledge regarding cancer radiobiology and the activation of radioresistance mechanisms emerged from studies using external beam radiation therapy (EBRT). Yet, less is known about the...

    Authors: Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli and Martin Behe
    Citation: Journal of Hematology & Oncology 2022 15:123
  46. Metabolic reprogramming of cancer cells within the tumor microenvironment typically occurs in response to increased nutritional, translation and proliferative demands. Altered lipid metabolism is a marker of t...

    Authors: Yahui Zhu, Xingrong Lin, Xiaojun Zhou, Edward V. Prochownik, Fubing Wang and Youjun Li
    Citation: Journal of Hematology & Oncology 2022 15:120

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here